A focused 2026 clinical landscape deep dive into NCT07593391, evaluating NNZ-2591 in Phelan-McDermid Syndrome: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07696871, evaluating Cannabidiol in Major Depressive Disorder: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into ChiCTR2600128158, evaluating Ropivacaine Hydrochloride in Migraine Prevention: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07480564, evaluating TSHA-102 in Rett Syndrome: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

CorMedix 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Mineralys Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Praxis Precision Medicines 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Edgewise Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Vera Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Roivant Sciences 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Nektar Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

MoonLake Immunotherapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.